Tandem Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Tandem Diabetes Care
TNDM Stock  USD 33.47  0.86  2.64%   
Tandem Diabetes financial statements provide useful quarterly and yearly information to potential Tandem Diabetes Care investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Tandem Diabetes financial statements helps investors assess Tandem Diabetes' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tandem Diabetes' valuation are summarized below:
Gross Profit
425.4 M
Profit Margin
(0.15)
Market Capitalization
2.2 B
Enterprise Value Revenue
2.576
Revenue
854.4 M
There are over one hundred nineteen available fundamental trend indicators for Tandem Diabetes Care, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to double-check Tandem Diabetes' current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 16th of February 2025, Enterprise Value is likely to grow to about 2.2 B

Tandem Diabetes Total Revenue

902.87 Million

Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 19 M, Interest Expense of 6 M or Selling General Administrative of 425.6 M, as well as many indicators such as Price To Sales Ratio of 2.81, Dividend Yield of 0.0 or PTB Ratio of 4.71. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
  
Check out the analysis of Tandem Diabetes Correlation against competitors.

Tandem Diabetes Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.2 B1.1 B442.2 M
Slightly volatile
Short and Long Term Debt Total501.9 M478 M168.9 M
Slightly volatile
Other Current Liabilities102.2 M97.3 M39.1 M
Slightly volatile
Total Current Liabilities235.8 M224.5 M87.5 M
Slightly volatile
Other Liabilities43.6 M41.5 M17.7 M
Slightly volatile
Property Plant And Equipment Net198.4 M189 M64.9 M
Slightly volatile
Accounts Payable59.9 M57 M25.4 M
Slightly volatile
Cash65.4 M67.7 M57.2 M
Slightly volatile
Non Current Assets Total247.1 M235.4 M78.1 M
Slightly volatile
Non Currrent Assets Other45.4 M43.2 M10.5 M
Slightly volatile
Cash And Short Term Investments565 M538.1 M248.3 M
Slightly volatile
Net Receivables127.5 M121.4 M50.4 M
Slightly volatile
Common Stock Total Equity71 K74.8 K927.2 K
Pretty Stable
Common Stock Shares Outstanding78.5 M74.7 M33 M
Slightly volatile
Short Term Investments493.9 M470.4 M190.7 M
Slightly volatile
Liabilities And Stockholders Equity1.2 B1.1 B442.2 M
Slightly volatile
Non Current Liabilities Total535.8 M510.3 M194.2 M
Slightly volatile
Inventory190.7 M181.6 M58.6 M
Slightly volatile
Other Current Assets20 M19.1 M7.3 M
Slightly volatile
Other Stockholder Equity1.5 B1.5 B681.3 M
Slightly volatile
Total Liabilities771.6 M734.9 M281.6 M
Slightly volatile
Property Plant And Equipment Gross262.2 M249.7 M74.7 M
Slightly volatile
Total Current Assets903.2 M860.2 M364 M
Slightly volatile
Short Term Debt29.9 M19.6 M24.7 M
Very volatile
Common Stock41.6 K75.9 K38.1 K
Slightly volatile
Property Plant Equipment82.8 M78.8 M33.9 M
Slightly volatile
Current Deferred Revenue53.1 M50.6 M13 M
Slightly volatile
Intangible Assets3.5 M3.2 M3.2 M
Slightly volatile
Long Term Debt344.2 M327.8 M153.9 M
Slightly volatile
Long Term Debt Total339.9 M323.7 M153.1 M
Slightly volatile
Capital Surpluse776.1 M1.3 B678.5 M
Slightly volatile
Deferred Long Term Liabilities3.6 M4.4 M3.4 M
Slightly volatile
Short and Long Term Debt58.9 M88 M58.6 M
Slightly volatile
Non Current Liabilities Other23.2 M36.6 M17.4 M
Slightly volatile
Net Invested Capital468.2 M688.5 M279.2 M
Slightly volatile
Net Working Capital436.4 M635.6 M252.8 M
Slightly volatile
Capital Stock68.4 K75.9 K60.8 K
Slightly volatile
Capital Lease Obligations76.2 M150.2 M47.3 M
Slightly volatile

Tandem Diabetes Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization19 M18.1 M8.3 M
Slightly volatile
Interest Expense6 M11.4 M5.5 M
Slightly volatile
Selling General Administrative425.6 M405.4 M169.4 M
Slightly volatile
Other Operating Expenses1.2 B1.1 B419.6 M
Slightly volatile
Research Development204.9 M195.1 M65.5 M
Slightly volatile
Total Operating Expenses725.6 M691.1 M249.4 M
Slightly volatile
Total Revenue902.9 M859.9 M338.1 M
Slightly volatile
Cost Of Revenue458.9 M437 M170.7 M
Slightly volatile
Interest Income27.6 M26.3 M6.9 M
Slightly volatile
Reconciled Depreciation11.5 M18.1 M9.4 M
Slightly volatile
Extraordinary Items41.3 M46.4 M50.6 M
Slightly volatile
Non Recurring24.8 M27.9 M30.5 M
Slightly volatile

Tandem Diabetes Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation106.4 M101.3 M40 M
Slightly volatile
Begin Period Cash Flow208.3 M198.4 M72.1 M
Slightly volatile
Depreciation19 M18.1 M8.3 M
Slightly volatile
Capital Expenditures62.3 M59.3 M20.9 M
Slightly volatile
Total Cash From Financing Activities4.5 M4.7 M58.4 M
Very volatile
End Period Cash Flow65.4 M67.7 M57.2 M
Slightly volatile
Sale Purchase Of Stock25.1 M20.2 M17.7 M
Slightly volatile
Change To Netincome147 M140 M60.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.812.9522.7299
Slightly volatile
Days Sales Outstanding92.5859.26118
Slightly volatile
Stock Based Compensation To Revenue0.150.140.1372
Very volatile
Capex To Depreciation1.552.961.9194
Slightly volatile
Inventory Turnover2.412.172.6203
Slightly volatile
Days Of Inventory On Hand176174217
Slightly volatile
Payables Turnover8.126.98.8349
Pretty Stable
Sales General And Administrative To Revenue0.880.922.4955
Slightly volatile
Research And Ddevelopement To Revenue0.250.260.8576
Slightly volatile
Capex To Revenue0.07540.07940.4804
Slightly volatile
Cash Per Share7.888.2937.3534
Pretty Stable
Days Payables Outstanding51.2954.7761.8088
Slightly volatile
Intangibles To Total Assets0.00320.00340.0223
Slightly volatile
Current Ratio3.263.453.7719
Pretty Stable
Receivables Turnover4.696.385.2171
Slightly volatile
Graham Number21.122.21147
Slightly volatile
Capex Per Share0.870.912.4625
Slightly volatile
Average Receivables1.1 M1.2 M1.3 M
Slightly volatile
Revenue Per Share22.6413.2517.927
Pretty Stable
Interest Debt Per Share7.167.5415.5686
Slightly volatile
Debt To Assets0.440.50.4195
Pretty Stable
Operating Cycle269234334
Slightly volatile
Days Of Payables Outstanding51.2954.7761.8088
Slightly volatile
Ebt Per Ebit1.270.851.4913
Pretty Stable
Long Term Debt To Capitalization0.460.430.4622
Pretty Stable
Quick Ratio2.822.723.2469
Pretty Stable
Net Income Per E B T1.11.161.0142
Slightly volatile
Cash Ratio0.330.351.2709
Slightly volatile
Cash Conversion Cycle218179273
Slightly volatile
Days Of Inventory Outstanding176174217
Slightly volatile
Days Of Sales Outstanding92.5859.26118
Slightly volatile
Fixed Asset Turnover4.354.14.6436
Slightly volatile
Debt Ratio0.440.50.4195
Pretty Stable
Price Sales Ratio2.812.9522.7299
Slightly volatile
Asset Turnover0.540.710.5977
Slightly volatile

Tandem Diabetes Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.6 B
Slightly volatile
Enterprise Value2.2 B2 B1.9 B
Slightly volatile

Tandem Fundamental Market Drivers

Forward Price Earnings1111.1111
Cash And Short Term Investments467.9 M

Tandem Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tandem Diabetes Financial Statements

Tandem Diabetes investors utilize fundamental indicators, such as revenue or net income, to predict how Tandem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue50.6 M53.1 M
Total Revenue859.9 M902.9 M
Cost Of Revenue437 M458.9 M
Stock Based Compensation To Revenue 0.14  0.15 
Sales General And Administrative To Revenue 0.92  0.88 
Research And Ddevelopement To Revenue 0.26  0.25 
Capex To Revenue 0.08  0.08 
Revenue Per Share 13.25  22.64 
Ebit Per Revenue(0.28)(0.29)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
How To Invest In Tandem
Details
Is Tandem Stock a good investment?
Details
What is Tandem Diabetes' Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Tandem Diabetes Correlation against competitors.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(1.94)
Revenue Per Share
13.082
Quarterly Revenue Growth
0.314
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY